[5 alpha-reductase inhibitors and prostate cancer: a statement of the Committee of Cancerology of the French Association of Urology].

Date publication

septembre 2012

Auteurs

Membres identifiés du Cancéropôle Est :
Pr CORMIER Luc , Dr ESCHWEGE Pascal

Tous les auteurs :
Eschwege P, Gaschignard N, Ploussard G, Peyromaure M, Bastide C, Cormier L, Mongiat-Artus P, Rozet F, Fromont G, Hennequin C, Renard-Penna R, Beuzeboc P, Richaud P, Soulie M, Salomon L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/22920332

Résumé

INTRODUCTION: Two randomised trials and negative conclusion of the FDA about inhibitors of 5 alpha-reductase in prevention of prostate cancer need a revision of the indications of these drugs. METHODS: After description of fundamentals data, review of the literature in PubMed library was performed to analyse the indications of these drugs according to the different stages of prostate cancer. RESULTS: Even if PCPT and REDUCE studies showed a decrease of cancers with the use of 5 alpha-reductase (5ARI) but with side effects, there is no indication for prostate cancer prevention by these drugs. In the same way, despite the results of REEDEM study, there is no indication of these drugs in active surveillance. CONCLUSION: Despite the large interest of these drugs, no recommendation can be given for indications of 5ARI in prevention or treatment of prostate cancer.

Référence

Prog Urol. 2012 Sep;22(10):555-60